The company was granted patent - corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.
Suven Life Sciences Ltd (Suven) has informed the exchanges that it has been granted a product patent from Singapore (11201507763R) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033.
The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, and Schizophrenia.
The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, and Schizophrenia.
uven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
Suven Life Sciences Ltd is currently trading at Rs 224.75, up by Rs 3.3 or 1.49% from its previous closing of Rs 221.45 on the BSE. The stock is currently trading above its 200 DMA.
In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
Suven Life Sciences Ltd is currently trading at Rs 224.75, up by Rs 3.3 or 1.49% from its previous closing of Rs 221.45 on the BSE. The stock is currently trading above its 200 DMA.
http://www.indiainfoline.com/article/news-top-story/suven-life-sciences-secures-a-product-patent-in-singapore-117101800296_1.html
No comments:
Post a Comment